echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Br J Cancer: Carcinoembryonic antigen CEA: a marker of disease progression after induction therapy in patients with metastatic colorectal cancer

    Br J Cancer: Carcinoembryonic antigen CEA: a marker of disease progression after induction therapy in patients with metastatic colorectal cancer

    • Last Update: 2021-08-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Carcinoembryonic antigen (CEA) is a glycoprotein involved in cell adhesion, usually produced in the gastrointestinal tissues during fetal development
    .


    The serum level of CEA in the blood of healthy individuals is usually low (0–5 ng/ml), but may be elevated in certain non-neoplastic diseases, including inflammatory bowel disease, hepatitis, pancreatitis, lung infections , and smokingPatients(rarely more than 10 ng/ml), as well aspatients withgastrointestinal cancer, lung cancer and breast cancer


    Carcinoembryonic antigen (CEA) is a glycoprotein involved in cell adhesion, usually produced in the gastrointestinal tissues during fetal development


    Although about two-thirds of patients with colorectal cancer (CRC) have elevated CEA, international guidelines do not recommend its use as a screening or diagnostic tool due to its low sensitivity and specificity
    .

    Screening and Diagnosis of Colorectal Cancer

    In metastatic CRC (mCRC), changes in serum CEA levels can be used with imaging to monitor the patient's response to systemic therapy
    .


    In particular, a series of retrospective studies in the past have shown that there is a correlation between the variation of CEA and the patient's chemotherapy response, indicating that it may predict disease progression (PD) and its role in avoiding CT scans


    In metastatic CRC (mCRC), changes in serum CEA levels can be used with imaging to monitor the patient's response to systemic therapy



    Research flow chart

    Research flow chart

    The results showed that the study included 1,178 CEA levels and radiology data from 434 patients
    .


    The best cut-off value determined according to the ROC curve shows that CEA can be distinguished from the progression of the disease by at least 120% from the lowest point.
    The sensitivity is 74%, the specificity is 78%, and 92% of the radiological assessments did not appear.
    PD can avoid 67% of CT scan monitoring



    However, in 26% of cases, the 120% CEA threshold did not detect imaging PD
    .


    To improve this problem, the researchers evaluated different clinically relevant thresholds based on the optimal sensitivity cut-off value



    ROC curve analysis

    ROC curve analysis

    All in all, the results of the study revealed that in mCRC with a baseline CEA ≥ 10 ng/mL, the level of CEA can accurately predict the patient's disease progression after the end of first-line induction therapy
    .

    The results of the study revealed that in mCRC with a baseline CEA ≥ 10 ng/mL, the level of CEA can accurately predict the patient's disease progression after the end of the first-line induction therapy
    .


    The results of the study revealed that in mCRC with a baseline CEA ≥ 10 ng/mL, the level of CEA can accurately predict the patient's disease progression after the end of the first-line induction therapy



    CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.